Trial Profile
Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients: CAM-VHH1 Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs SGMIB anti-HER2 monoclonal antibody I-131 (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Adverse reactions
- Acronyms CAM-VHH1
- Sponsors Camel-IDS; Precirix
- 20 Jun 2018 Status changed from recruiting to completed.
- 05 Jun 2018 Results (n=9) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 24 Feb 2016 New trial record